On 26 May 2025, DocMorris AG settled on its rights offering with gross proceeds of CHF 208 million. The proceeds will be used to finance the planned medium-term growth in the prescription medicines (Rx) business, including incrementally targeted Rx marketing spend, as well as a potential repayment of the CHF 95 million convertible bond in September 2026. As part of its rights offering, DocMorris issued 36,182,790 new registered shares on 21 May 2025, which were listed on SIX Swiss Exchange on 22 May 2025. The capital increase was accompanied by a nominal value reduction from CHF 30.00 to CHF 0.01.
CapLaw Themes
- FinSA (FIDLEG) (32)
- FinIA (FINIG) (11)
- Insurance (8)
- Securities (92)
- Regulatory (128)
- Takeover (19)
- Derivatives (7)
- News, Deals & Cases (450)
- Events (149)
- Other Areas (8)
CapLaw PDF Archive
Discover more articles
We provide up-to-date information on legal and regulatory developments regarding the capital markets, publish concise articles on developments in the Swiss and international financial markets, and announce recent deals and forthcoming events.